Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | 1 | — | OT |
HCP calling on behalf of their wife to report after receiving CAPVAXIVE, their wife experienced nausea, vomiting, fatigue, weakness and a fever. Caller states their wife received the PNEUMOVA23 in 2017 and had similar reactions but is unsure if they; HCP calling on behalf of their wife to report after receiving CAPVAXIVE, their wife experienced nausea, vomiting, fatigue, weakness and a fever. Caller states their wife received the PNEUMOVA23 in 2017 and had similar reactions but is unsure if they; HCP calling on behalf of their wife to report after receiving CAPVAXIVE, their wife experienced nausea, vomiting, fatigue, weakness and a fever. Caller states their wife received the PNEUMOVA23 in 2017 and had similar reactions but is unsure if they; HCP calling on behalf of their wife to report after receiving CAPVAXIVE, their wife experienced nausea, vomiting, fatigue, weakness and a fever. Caller states their wife received the PNEUMOVA23 in 2017 and had similar reactions but is unsure if they; HCP calling on behalf of their wife to report after receiving CAPVAXIVE, their wife experienced nausea, vomiting, fatigue, weakness and a fever. Caller states their wife received the PNEUMOVA23 in 2017 and had similar reactions but is unsure if they; This spontaneous report was received from a physician and refers to a 74-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 07-Mar-2025, the patient started therapy with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE), dose number 1, administered by Intramuscular route (lot # and expiration date were not reported) for routine vaccination. On 07-Mar-2025, the patient experienced nausea, vomiting, fatigue, weakness (asthenia) and a fever (pyrexia). At the reporting time, the patient had not recovered from the events. The causal relationship between the events and Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was unknown.